Technology Listings


145 Results Sort By:
Combination Therapy to Overcome Resistance to Platinum-Based Chemotherapy
Application MAST1 inhibitors to overcome resistance to platinum-based chemotherapy, exacerbated by dexamethasone co-administration. Key Benefits Co-administration of MAST1 inhibitor and MAST1-stabilizing protein inhibitor abrogates tumor resistance to cisplatin MAST1 inhibitor, lestaurtinib, has previously reached phase III clinical trials and...
Published: 8/25/2021       Contributor(s): Sumin Kang, Jing Chen
Repurposed Treatment for Cocaine Use Disorder
Application Repurposed drug for transcriptomic-driven treatment of cocaine use disorder. Key Benefits FDA-approved drug. Outperformed current targets undergoing clinical trials for CUD at the mRNA level. Market Summary In 2018, there were approximately 2.2 million regular users of cocaine in the United States, and 1 million individuals with...
Published: 1/23/2021       Contributor(s): Rohan Palmer, Spencer Huggett
Natural Antimicrobial Compound to Treat Multidrug Resistant Infections
Application Pentagalloylglucose and extracts of Anacardiaceae to treat multidrug resistant bacterial and fungal infections. Key Benefits Potential compounds to combat multidrug-resistant pathogens. Natural compound isolated from Schinus plants. Antibiotic activity against multidrug-resistant bacteria and fungi. Low likelihood to contribute to...
Published: 12/9/2020       Contributor(s): Cassandra Quave, Francois Chassagne, Lewis Marquez, Micah Dettweiler, Julia Kubanek, Anne Sweeney-Jones, Bhuwan Chhetri
CFTR Modulators for Treating Rare Forms of Cystic Fibrosis
Application Small molecules to treat cystic fibrosis and other pulmonary diseases. Key Benefits Rescue rare variants of CFTR gene. Serve as PDE4 inhibitors with strong anti-inflammatory effects. Market Summary Cystic fibrosis (CF) is a progressive, genetic disorder that arises from mutations in the cystic fibrosis transmembrane conductance...
Published: 11/2/2020       Contributor(s): Eric Sorscher, Jeong Hong, Haian Fu, Yuhong Du, Huw Davies, Andras Rab, Candela Manfredi, Xun Yang, Zhi Ren
Small Molecule for Treatment or Prevention of Uremic Cardiomyopathy
Application Small molecule urea transporter (UT) inhibitors to treat or prevent conditions associated with chronic kidney disease. Key Benefits Provides a cardio-protective benefit in CKD patients. Suppresses cardiac hypertrophy and fibrosis. Market Summary Cardiovascular complications commonly occur in patients with chronic kidney disease...
Published: 11/2/2020       Contributor(s): Jeff Sands, Janet Klein, Xiaonan Wang
Photocaged Cytokines for Cancer Immunotherapy
Application Light-responsive cytokine prodrugs with controlled activation for improved cancer immunotherapy. Key Benefits Prolonged circulation and biased immune cell-selectivity. Controlled local activation, reduces off-target toxicity. Requires less frequent dosing. Market Summary While recombinant cytokines hold great potential for cancer...
Published: 11/2/2020       Contributor(s): Erik Dreaden, Lacey Perdue, Priscilla Do
Targeted Theranostic NanoToxin for Treating Metastatic and Drug-resistant Tumors
Application Magnetic theranostic nano-toxin for imaging and drug delivery applications in cancer therapy. Key Benefits Induces tumor cell death via a different biological mechanism, compared to current chemotherapeutics, to overcome drug resistance mechanisms in tumor cells. Delivers high levels of therapeutic agents into metastatic tumors, while...
Published: 11/2/2020       Contributor(s): Lily Yang, Xiangxue Guo, Hui Mao, Wei Chen
Additives that Increase Storage and Shelf Life of Platelets
Application Monoclonal antibody additive that inhibits ectodomain shedding of a platelet glycoprotein to improve platelet storage. Key Benefits Current storage techniques allows for limited storage times (5-7 days). New additive may enable platelet storage at 4°C, increase platelet storage time, and improve quality of stored platelets. Inhibits...
Published: 11/2/2020       Contributor(s): Renhao Li
PNP-based Solid Tumor Therapy in Conjunction with Checkpoint Blockade Inhibitors
Application Treatment of solid tumors combining purine nucleoside phosphorylase (PNP) technology with checkpoint blockade inhibition. Key Benefits Safe and effective method for markedly enhancing checkpoint blockade therapy for refractory tumors. Checkpoint inhibitor therapy is FDA-approved and already in use. Market Summary Checkpoint blockade...
Published: 10/22/2020       Contributor(s): Eric Sorscher, Turang Behbahani, Regina Rab, Annette Ehrhardt, Jeong Hong, Disha Joshi
Galectin-9 Directed CAR T-cells for Overcoming Resistance to Chemotherapy in Hematological Malignancies
Application Anti-human Galectin-9-directed chimeric antigen receptor (CAR) T-cells for treatment of hematological malignancies (B-ALL, T-ALL, and DLBCL) in normal, overweight, and obese patients. Key Benefits Can be used as a stand-alone or in-combination product to treat patients with hematological malignancies, particularly overweight and obese...
Published: 10/13/2020       Contributor(s): Curtis Henry, Miyoung (Mi-Young) Lee, Sunil Raikar, Jamie Hamilton, Anthony Ross
1 2 3 4 5 6 7 8 9 10 ...